ALAina Liu

Aina Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aina Liu has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Wenjing Gong

    The Affiliated Yantai Yuhuangding Hospital of Qingdao University

    5 shared publications
  • Ping Sun

    Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China

    4 shared publications
  • Ping Sun

    Department of Oncology, Yantai Yuhuangding Hospital, Shandong University, Yantai, China

    4 shared publications
  • Fei Li

    Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University

    3 shared publications
  • Ming Li

    Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University

    3 shared publications
  • Zeyu Liu

    Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University

    3 shared publications

Latest Publications

  • Open Access

    Deep learning-based radiomics and pathomics for decoding tumor microenvironment and predicting immunotherapy outcomes in gastric cancer

    by Xinyi Shen, Zeyu Liu, Wenjuan Yu, Fei Li, Yuxiao Lu, Ming Li, Ping Sun, Aina Liu

    Although immune checkpoint inhibitors have reshaped the therapeutic landscape of gastric cancer, durable responses are achieved in only a minority of patients. The tumor microenvironment, particularly immune-cell composition and spatial organization, critically modulates cancer progression and the efficacy of immune checkpoint inhibitors. Nevertheless, the lack of clinically accessible approaches for spatially resolving the tumor immune contexture, whether by direct pathological quantification or indirect radiomic inference, has hindered a mechanistic understanding of how it dictates immunotherapy outcomes. Deep learning-based radiomics and pathomics extract high-dimensional phenotypic information from radiological and pathological images, thereby characterizing tumors at macroscopic and microscopic scales. Each modality, however, captures only a partial view of the tumor microenvironment. Multimodal models can integrate complementary imaging features associated with tumor heterogeneity and spatial immune organization, thus improving predictive performance and linking multimodal features to immune-related biological processes. In this review, we summarize recent advances in deep learning-based radiomics, pathomics, and multimodal frameworks for decoding the immune microenvironment and predicting immunotherapy outcomes in gastric cancer. We also discuss their potential to complement established biomarkers and support personalized treatment decisions. Finally, we highlight key challenges, including limited data availability, interinstitutional variability, insufficient external validation, poor interpretability, and barriers to clinical implementation. Addressing these limitations may accelerate the development of robust imaging biomarkers for guiding immunotherapy decisions in gastric cancer.

  • Open Access

    Interpretable machine learning for predicting immunotherapy response in gastric cancer via serum cytokine profiling and organoid co-culture platforms

    by Ruyue Chen, Tianxiang Geng, Peng Xiao, Yifei Zhang, Xixun Wang, Zhi Yu, Aina Liu, Lixin Jiang, Miaomiao Li, Xicheng Song, et al.

    Background Immunotherapy has become a promising strategy for gastric cancer, yet predicting treatment response remains challenging. We developed an exploratory, biologically informed machine learning framework integrating peri-treatment serum biomarkers and clinical variables, with candidate cytokines informed by an in vitro patient-derived organoids (PDOs)–cancer-associated fibroblasts (CAFs)–T cells co-culture platform, to assess pathological response to PD-1 inhibitor (PD-1i)-based therapy in gastric cancer. Methods Data from 125 patients receiving PD-1i were analyzed. Serum samples collected before and after immunotherapy were tested for cytokines. Eighteen successfully established PDOs-CAFs-T cells co-culture models were used for cytokine profiling and to identify seven candidate cytokines. These cytokines were subsequently measured in paired serum samples from the 125-patient clinical cohort and combined with clinicopathological variables for machine learning model development. Tumor Regression Grade (TRG) served as the binary outcome variable, representing patients with good versus poor/no tumor regression. Experimental and clinical data were used to train predictive models with multiple algorithms, including CatBoost and several other machine learning methods. Model performance was assessed by tenfold cross-validation, ROC, precision-recall (PR) Curve, and decision curve analyses. Feature importance was interpreted using Shapley additive explanations (SHAP) and visualized using decision tree. Results The PDOs-CAFs-T cells co-culture platform showed cytokine-change trends that were generally concordant with those observed in patient serum after treatment. 10 key predictors were identified, including pre-/post-treatment maximum diameter, ycT/ycN stages, and pre- or post-treatment cytokines (IFN-α2, IL-2, IL-6, IL-8, MCP-1). In the internal testing set, the tuned CatBoost model achieved an AUC of 0.845. SHAP analysis revealed post-treatment maximum diameter and cytokine profiles as the most influential features. Decision trees clearly and interpretably present the model. Conclusion This study presents an exploratory, biologically informed machine learning framework for peri-treatment assessment of pathological response in gastric cancer. The PDOs-CAFs-T cells co-culture platform provided biological context for candidate cytokine selection.

  • The Progress of Tertiary Lymphoid Structures in Gastric Cancer

    by Fei Li, Wenjing Gong, Aina Liu

    Gastric cancer is one of the leading causes of cancer-related death worldwide, ranking fourth in mortality and fifth in incidence (Ilic & Ilic, 2022). For patients with advanced gastric cancer, tre...

  • Open Access

    Efficacy and safety of immunotherapy rechallenge in second-line treatment after failure of first-line immune checkpoint inhibitors combined with chemotherapy in advanced gastric cancer: a retrospective study

    by Fei Li, Wenjing Gong, Miaomiao Yang, Aina Liu

    Background: Gastric cancer is one of the most common malignant tumors worldwide, ranking fifth in incidence and fourth in mortality. While immune checkpoint inhibitor (ICI) combined chemotherapy has become the standard first-line treatment for advanced gastric cancer (AGC), most patients eventually experience disease progression. Currently, there is no unified consensus on second-line treatment strategies following failure of ICI combined chemotherapy. Immunotherapy rechallenge has shown potential efficacy in non-small cell lung cancer and melanoma, but its efficacy in AGC remains unclear. This retrospective study analyzed the effectiveness and safety of immunotherapy rechallenge versus chemotherapy in second-line treatment for AGC patients. Methods: We retrospectively analyzed 83 AGC patients who progressed after first-line treatment with ICI combined chemotherapy at Qingdao University Affiliated Yantai Yuhuangding Hospital between December 2021 and March 2025. Among them, 49 patients received immunotherapy rechallenge and 34 patients received chemotherapy as second-line therapy. Efficacy was assessed according to the RECIST v1.1 criteria, including Objective Response Rate (ORR), Disease Control Rate (DCR), Progression-Free Survival (PFS), Overall Survival (OS), and treatment-related adverse events (TRAEs) of grade 3 or higher. Results: Immunotherapy rechallenge demonstrated superior outcomes compared with chemotherapy, with higher ORR (30.6% vs. 6.0%) and DCR (83.7% vs. 38.3%). Median PFS and median OS were 4.57 vs. 2.20 months and 12.4 vs. 5.33 months, respectively. Cox regression analysis showed that second-line treatment modality, PD-L1 expression, and pathological type were independent prognostic factors for OS, whereas PFS was only influenced by treatment modality. In subgroup analysis, patients with CPS ≥1 derived significant benefit from immunotherapy rechallenge in both mPFS (4.83 vs. 2.20 months) and mOS (12.6 vs. 7.13 months, P<0.01), whereas no significant difference were observed in CPS<1 patients. Grade ≥3 TRAEs occurred in 26.5% of patients in the immunotherapy rechallenge group versus 35.3% in the chemotherapy group (p=0.049). Conclusion: For AGC patients who progressed after first-line ICI combined chemotherapy, immunotherapy rechallenge confers significant survival benefits compared to chemotherapy. Immunotherapy rechallenge is more effective in patients with high PD-L1 expression, suggesting its potential clinical application value as second-line treatment regimen.


  • Open Access

    Real-World Efficacy of Cadonilimab Plus Chemotherapy as Second-Line Therapy in Immunotherapy-Pretreated Advanced HER2 Negative Gastric or Gastroesophageal Junction Cancer

    by Zeyu Liu, Yuxiao Lu, Ming Li, Jinyu Xiang, Ping Sun, Aina Liu

    Background: Immunotherapy is now a cornerstone of first-line treatment for advanced gastric or gastroesophageal junction cancer (G/GEJC). However, optimal second-line options after progression on first-line immunotherapy are undefined. Given the established efficacy of cadonilimab in the first-line setting, this real-world study evaluated its combination with chemotherapy as a second-line treatment. Methods: We conducted a single-center retrospective study of patients with advanced G/GEJC progressing after first-line immunotherapy. Patients received either cadonilimab plus chemotherapy (Cohort A, n=50) or chemotherapy alone (Cohort B, n=62) as second-line therapy between October 2022 and April 2025. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety. Results: Cohort A showed significantly improved outcomes. Median PFS was 4.9 months (95% CI: 3.9– 6.0) in Cohort A vs 3.8 months (95% CI: 2.8– 4.8) in Cohort B (p=0.024). Median OS was 10.3 months (95% CI: 8.8– 11.8) vs 7.4 months (95% CI: 6.9– 7.9), respectively (p=0.046). ORR was 34.0% vs 17.7% (p=0.048), and DCR was 74.0% vs 54.8% (p=0.036). Safety was comparable between cohorts, with no treatment-related deaths. Conclusion: Cadonilimab plus chemotherapy significantly improved efficacy outcomes versus chemotherapy alone in patients with advanced G/GEJC after first-line immunotherapy progression, with a manageable safety profile. This suggests cadonilimab based therapy is a promising second-line strategy. Further prospective randomized studies are needed to confirm these findings.


  • SHMT proteins: An emerging set of serine hydroxymethyltransferase in cancer

    by Rong Fu, Fulin Sun, Wenbo Wang, Ruixuan Wang, Huhu Zhang, Xinping He, Aina Liu, Lina Yang


  • Open Access

    Efficacy and safety of anlotinib for triple-negative breast cancer with brain metastases

    by Zeyu Liu, Ming Li, Ziyi Zhao, Aina Liu, Ping Sun

    Background: The anti-angiogenic agent anlotinib offers a new treatment option for triple-negative breast cancer (TNBC) patients with brain metastases. This study aimed to evaluate the efficacy and safety of anlotinib in the treatment of TNBC patients with brain metastases.Methods: Between October 2019 and April 2024, 29 TNBC patients with brain metastases who had failed prior therapy and were treated with anlotinib were retrospectively analyzed. The primary endpoint was central nervous system (CNS) progression-free survival (PFS), and secondary endpoints included overall survival (OS), intracranial disease control rate (iDCR), intracranial objective response rate (iORR), and safety.Results: The median CNS PFS of 29 patients was 7.2 months (95% confidence interval [CI], 3.5-10.9 months), and the median OS was 10.2 months (95% CI, 5.6-14.8 months). The iORR and iDCR were 31.0% and 86.2%, respectively. Five patients (17.2%) experienced grade 3-4 adverse events (AEs), with bone marrow suppression (2/29, 6.9%) being the most common. Most AEs were clinically manageable, and no treatment-related death was observed.Conclusion: Anlotinib demonstrated encouraging efficacy and manageable toxicity in the treatment of TNBC patients with brain metastases who had failed standard treatment.


  • Open Access

    Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study

    by Jinyu Xiang, Wenjing Gong, Ping Sun, Xuan Wang, Aina Liu

    Background: Nivolumab combined with chemotherapy has been shown to improve prognosis in patients with untreated, human epidermal growth factor receptor 2 (HER2)-negative advanced gastric cancer (GC) and programmed death ligand-1 (PD-L1) combined positive score (CPS) ≥5. However, the available first-line treatment options for advanced GC are limited. Analysis of efficacy and safety of other programmed cell death protein 1 (PD-1) antibodies combined with chemotherapy may provide alternative treatment options. Methods: This retrospective study included patients with untreated, HER2-negative, unresectable locally advanced, or metastatic GC or gastroesophageal junction (GEJ) cancer who received either camrelizumab combined with oxaliplatin plus S-1 (SOX)/capecitabine plus oxaliplatin (CapeOX) or SOX/CapOX alone between November 2020 and April 2022. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety were evaluated. Results: This study included 49 patients in camrelizumab plus chemotherapy group and 54 in chemotherapy group. The baseline clinical characteristics beyond Epstein-Barr virus (EBV) status and PD-L1 CPS had no difference between combination group and chemotherapy group. ORR and DCR were significantly higher in combination therapy group than in chemotherapy group (59.18% vs. 38.89%, P=0.048; 83.67% vs. 62.96%, P=0.018). The median PFS in combination group was significantly longer than chemotherapy group [10.03 vs. 6.24 months, hazard ratio (HR) 0.603, 95% confidence interval (CI): 0.368–0.989, P=0.045]. The OS was not mature at the time of the OS analysis, with 40% patients died. Subgroup analyses showed that PFS was longer in patients with PD-L1 CPS ≥1 compared with CPS vs. 54% in chemotherapy group), anemia (39% vs. 33%, respectively), and thrombocytopenia (39% vs. 33%, respectively). The proportion of reactive cutaneous capillary endothelial proliferation (RCCEP, 73% vs. 0%) was higher in combination group relative to chemotherapy group; all were grades 1–2. Conclusions: Among patients treated with camrelizumab combined with chemotherapy, the clinical outcomes were superior to those patients treated with chemotherapy. However, these promising findings need to be confirmed in future clinical trials.


  • Open Access

    Complete remission of alpha-fetoprotein-producing gastric cancer by combined tislelizumab-apatinib treatment of a patient with proficient mismatch repair: a case report

    by Jinyu Xiang, Wenjing Gong, CongCong Wang, Ping Sun, Aina Liu

    Alpha‑fetoprotein-producing gastric cancer (AFPGC) is a rare type of gastric cancer with a high rate of metastasis and poor prognosis. Despite substantial progress in the treatment of many solid tumors, there are no reports of the safety and effectiveness of immune checkpoint inhibitors in combination with antiangiogenesis agents for AFPGC patients who have proficient mismatch repair. We describe a 69-year-old man who was diagnosed with metastatic AFPGC. After progression to chemotherapy resistance, tislelizumab combined with apatinib was administered, although the patient’s gastroscopic pathology showed proficient mismatch repair. After three cycles of therapy, partial remission (reduced by 56%) was obtained, and the quality of life improved significantly. Surprisingly, after more than 1 year of continuous application of the combination treatment regimen, both the primary and metastatic tumors in this patient eventually disappeared, which obtained complete remission without surgery. The patient has had a progression-free survival of more than 24 months and is still continuing to benefit. This case is the first example of effective treatment of AFPGC with tislelizumab combined with apatinib. The outcomes of this case suggest a highly effective and tolerable therapeutic strategy for microsatellite-stabilized AFPGC.


  • Open Access

    Prognostic value of insulin‑like growth factor 2 mRNA‑binding protein 3 and vascular endothelial growth factor‑A in patients with primary non‑small‑cell lung cancer

    by Jiannan Liu, Ying Liu, Wenjing Gong, Xiangshuo Kong, Congcong Wang, Shuhua Wang, Aina Liu

    Insulin‑like growth factor 2 mRNA‑binding protein 3 (IMP3) and vascular endothelial growth factor‑A (VEGF‑A) may play important roles in the process of tumor progression and tumor angiogenesis. The aim of the present study was to examine the co‑expression of IMP3 and VEGF‑A in primary human non‑small cell lung cancer (NSCLC), to investigate the association between these two expression levels and determine the clinicopathological implications, including changes to microvessel density (MVD), and to assess the prognostic value of co‑expression. Using immunohistochemical staining, the expression of IMP3, VEGF‑A and CD34 expression was detected in 128 primary NSCLC tissue samples. According to the expression of IMP3 and VEGF‑A, the cases were divided into four groups. Next, the clinicopathological features, MVD and survival time were investigated across the different groups. The immunohistochemical analyses demonstrated that there was a significant correlation between IMP3 and VEGF‑A expression in NSCLC (r=0.181; P=0.041). Co‑expression of IMP3 and VEGF‑A was significantly associated with larger primary tumor size (P=0.016), poorer differentiation (P=0.014), more advanced Tumor‑Node‑Metastasis stage (P=0.012), increased MVD (P=0.004) and positive lymph node metastasis (P=0.002). Survival analysis demonstrated that cases with IMP3 and VEGF‑A double‑positive staining were significantly associated with lower survival rates compared with cases with double‑negative staining (P=0.039). In the early NSCLC (I‑IIa) subgroup, the mean survival time of the double‑positive staining group was significantly shorter compared with that of the double‑negative staining group (P=0.015). Co‑expression of IMP3 and VEGF‑A was associated with angiogenesis and a poorer prognosis in NSCLC, and may therefore play a critical role in NSCLC progression.